Clinical trials · Charleston, SC
Alpha 1-Antitrypsin Deficiency clinical trials in Charleston
We’re tracking 3 recruiting alpha 1-antitrypsin deficiency studies with a site in or near Charleston — including Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Charleston
- NCT06049082RecruitingPhase 1
A study of KB408 for alpha-1 antitrypsin deficiency
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
Charleston, South CarolinaAges 18–70 - NCT06389877RecruitingPhase 1/Phase 2
Testing BEAM-302 for alpha-1 antitrypsin deficiency
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
Charleston, South CarolinaAges 18–70 - NCT07555483RecruitingPhase 3
Weekly injection vs IV infusion for alpha-1 antitrypsin deficiency
This trial tests whether a new weekly injection form of alpha-1 antitrypsin replacement therapy (a protein your body lacks) works as well as the standard IV infusion you may currently receive. The goal is to offer a more convenient treatment option for people with alpha-1 antitrypsin deficiency (a genetic lung condition).
Charleston, South CarolinaAges 18–80
Hear when a new Alpha 1-Antitrypsin Deficiency trial opens near Charleston, SC
We’ll email you when one opens near Charleston, SC — at most once a week, no account needed, unsubscribe anytime.
Alpha 1-Antitrypsin Deficiency trials in other cities
Where these studies are running near Charleston
Institutions with a site for the recruiting alpha 1-antitrypsin deficiency studies listed above.
- Clinical Study Center
- GC2501 Study Site 101
- Medical University of South Carolina
What taking part in a alpha 1-antitrypsin deficiency study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting alpha 1-antitrypsin deficiency studies in South Carolina.
Common questions
- Are there alpha 1-antitrypsin deficiency clinical trials near Charleston?
- Yes. We're currently tracking 3 recruiting alpha 1-antitrypsin deficiency studies with a site near Charleston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alpha 1-antitrypsin deficiency study near Charleston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Charleston to take part?
- Not necessarily. These studies have a site near Charleston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alpha 1-antitrypsin deficiency trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alpha 1-antitrypsin deficiency studies open near Charleston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.